Tectonic Therapeutic to Present Phase 1b Data for TX45 at European Society of Cardiology Heart Failure 2025

Rhea-AI Summary

Tectonic Therapeutic (NASDAQ: TECX) has announced an upcoming late-breaking oral presentation at the European Society of Cardiology (ESC) Heart Failure 2025 Congress in Belgrade, Serbia. The presentation will showcase the complete Phase 1b results for TX45, the company's lead asset designed as a long-acting relaxin therapy for patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF).

The presentation, scheduled for May 17, 2025, will expand upon the interim data previously disclosed on January 30, 2025. Chief Development Officer Anthony Muslin, MD, will present the hemodynamic effects of TX45, which is being developed as a potential best-in-class therapy. The session will focus on late-breaking science in heart failure, cardiomyopathies, pulmonary hypertension, and valvular heart disease.

Positive

• Selected for late-breaking presentation at major cardiology congress
• Phase 1b trial completed with full results to be presented
• Expanding upon previously announced interim data indicates continued progress

Negative

• None.

Late-breaking oral presentation to include full Phase 1b results for TX45 in the Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”) cohort

WATERTOWN, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”), today announced that it will make a late-breaking oral presentation at the European Society of Cardiology (ESC) Heart Failure 2025 Congress. The presentation will highlight Phase 1b data for TX45, Tectonic’s lead asset and a long-acting relaxin therapy as a potential best-in-class therapy for patients with Group 2 PH-HFpEF. The presentation at ESC Heart Failure 2025 will include the full Phase 1b PH-HFpEF cohort results for TX45, expanding on the interim data previously announced by Tectonic on January 30, 2025.

ESC Heart Failure 2025 Presentation Details (being held in Belgrade, Serbia, May 17-20, 2025):

• Title: Hemodynamic effects of TX45 , a long-acting Fc-relaxin fusion, in Group 2 pulmonary hypertension patients.
• Presenter: Anthony Muslin, MD, Chief Development Officer
• Session: Late-breaking science in heart failure, cardiomyopathies, pulmonary hypertension, and valvular heart disease
• Session Date: Saturday, May 17, 2025
• Session Time: 4:40 p.m. Central European Time / 10:40 a.m. Eastern Time
  

About TX45, a long-acting Fc-relaxin fusion protein
TX45 is an Fc-relaxin fusion protein with optimized pharmacokinetics and biophysical properties that activates the RXFP1 receptor, the G-protein coupled receptor target of the hormone relaxin. Relaxin is an endogenous protein, expressed at low levels in both men and women that is a pulmonary and systemic vasodilator with lusitropic, anti-fibrotic and anti-inflammatory activity. In normal human physiology, relaxin is upregulated during pregnancy where it exerts vasodilative effects, reduces systemic and pulmonary vascular resistance and increases cardiac output to accommodate the increased demand for oxygen and nutrients from the developing fetus. Relaxin also exerts anti-fibrotic effects on pelvic ligaments to facilitate delivery of the baby.

About Group 2 Pulmonary Hypertension in HFpEF
The World Health Organization has defined 5 groups of pulmonary hypertension (“PH”). Tectonic is focused on the Group 2 subtype, a condition that develops due to left-sided heart disease, specifically Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF”). In patients with PH-HFpEF, chronic heart failure leads to increased blood pressure in the pulmonary arteries, exerting severe strain on the right side of the heart, which adapts poorly to the increased pressure. This increased pulmonary pressure gradually causes worsening exercise capacity, shortness of breath and right-sided heart failure which can lead to death. PH-HFpEF is further segmented based on pulmonary hemodynamics into Isolated, post-capillary PH (“IpcPH”) and Combined pre- and post-capillary PH (“CpcPH”). CpcPH is more severe, accounts for about one third to one half of the 1.4 million PH-HFpEF patients in the U.S. and is characterized by additional, abnormal changes to the pulmonary vasculature, leading to an increase in Pulmonary Vascular Resistance (“PVR”). Although several Group 1 PH (Pulmonary Arterial Hypertension, “PAH”) medications have been explored in Group 2 PH, to date, no medications have been approved for its treatment.

About Tectonic
Tectonic Therapeutic is a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Leveraging its proprietary technology platform called GEODe™ (GPCRs Engineered for Optimal Discovery), Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Tectonic focuses on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, as these are areas where new medicines have the potential to improve patient quality of life. Tectonic is headquartered in Watertown, Massachusetts. For more information, please visit www.tectonictx.com and follow us on LinkedIn.

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are “forward-looking statements. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding the potential therapeutic benefit of TX45. These forward-looking statements are based on Tectonic’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Tectonic’s clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the impacts of macroeconomic conditions, including the conflict in Ukraine and the conflict in the Middle East, heightened inflation and uncertain credit and financial markets, on Tectonic’s business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; Tectonic’s ability to realize the benefits of its collaborations and license agreements; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; and unexpected litigation or other disputes. Other factors that may cause Tectonic’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified under the heading “Risk Factors” in Tectonic’s annual report on Form 10-K filed with the SEC on March 20, 2025, and in other filings that Tectonic makes and will make with the SEC in the future. Tectonic expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. For more information, please visit www.tectonictx.com and follow us on LinkedIn.

Contact:

Dan Ferry
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576

FAQ

What will be presented about TECX's TX45 at ESC Heart Failure 2025?

Complete Phase 1b results showing hemodynamic effects of TX45 in Group 2 PH-HFpEF patients, expanding on interim data from January 2025.

When and where will TECX present the TX45 Phase 1b data?

May 17, 2025, at 4:40 PM CET in Belgrade, Serbia, during the ESC Heart Failure 2025 Congress.

What condition is TECX's TX45 being developed to treat?

TX45 is being developed for Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF).

How does TECX's TX45 work as a therapeutic treatment?

TX45 is a long-acting relaxin therapy, designed as an Fc-relaxin fusion protein that modulates G-protein coupled receptors (GPCRs).